
Neumora Therapeutics, Inc. Common Stock
NMRA
NMRA: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
moreShow NMRA Financials
Recent trades of NMRA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NMRA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Machine learning systems for generating multi-modal data archetypes Aug. 29, 2023
-
Patent Title: Machine learning-based diagnostic classifier Aug. 01, 2023
-
Patent Title: Machine learning-based diagnostic classifier Jun. 13, 2023
-
Patent Title: Machine learning systems for processing multi-modal patient data Jun. 06, 2023
Federal grants, loans, and purchases
Followers on NMRA's company Twitter account
Number of mentions of NMRA in WallStreetBets Daily Discussion
Recent insights relating to NMRA
Recent picks made for NMRA stock on CNBC
ETFs with the largest estimated holdings in NMRA
Flights by private jets registered to NMRA